Joseph Gut - thasso
Posted in New Drug Approval, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
October 31, 2018 – The American Food and Drug Administration (FDA) recently approved Cemiplimab-Rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
…
Joseph Gut - thasso
Posted in Genetic Background, New Drug Approval, Rare Diseases, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
August 14, 2018 – The American Food and Drug Administration (FDA) just approved Patisiran (Onpattro) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.
…
Joseph Gut - thasso
Posted in Ethnicity, Genetic Background, New Research, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
November 24, 2017 – New research indicates that one-size treatment for one form of blood cancer likely does not fit all, particularly when it comes to ethnic differences of patients. Thus, African-American men are three times more likely to be diagnosed with multiple myeloma,
…
Joseph Gut - thasso
Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
…
Joseph Gut - thasso
Posted in Genetic Background, In The Press, New Drug Approval, Personalized Medicine, Pharmacogenetics, Rare Diseases, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
1 Comment ↓
September 19, 2016 – This post presents below a virtually unedited announcement by the American Food & Drug Administration (FDA) concerning Duchenne Muscular Dystrophy (DMD) therapy option which gives much hope for at least some of the affected patients.
…
Joseph Gut - thasso
Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
…
Joseph Gut - thasso
Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
April 12, 2016 – The American Food and Drug Administration (FDA) just approved Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with a least one prior therapy.
…
Joseph Gut - thasso
Posted in Allelische Variante, New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
July 13, 2015 – This post persents a press announcement by the U.S. Food and Drug Administration (FDA). The text has slightly been edited by the autor of this blog. Thus, FDA today approved Gefinitib (Iressa) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations,
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
March 22, 2015 – This post addresses a topic which often gets lost in the current hype on targeted and precision (theragenomic) medicine. The issue is that targeted therapies are not only very precise and highly effective (in most patients) but they often also come with considerable clinical toxicity.
…
Optional: Social Subscribe/Login
thasso: recent comments